-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Synaptogenix (SNPX) Vs. Its Competitors Financial Review
Synaptogenix (SNPX) Vs. Its Competitors Financial Review
Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Synaptogenix and its rivals, as provided by MarketBeat.
Get Synaptogenix alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Synaptogenix | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix Competitors | 3141 | 13133 | 39362 | 635 | 2.67 |
Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synaptogenix is more favorable than its rivals.
Volatility and Risk
Synaptogenix has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Synaptogenix's rivals have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.Valuation and Earnings
This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Synaptogenix | N/A | -$12.61 million | -3.19 |
Synaptogenix Competitors | $1.83 billion | $243.52 million | -4.11 |
Synaptogenix's rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by company insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Synaptogenix and its rivals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Synaptogenix | N/A | -45.23% | -43.73% |
Synaptogenix Competitors | -3,202.84% | -160.99% | -24.58% |
Summary
Synaptogenix rivals beat Synaptogenix on 7 of the 13 factors compared.
Synaptogenix Company Profile
(Get Rating)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Synaptogenix(纳斯达克代码:SNPX-GET Rating)是962家上市公司之一,但它与竞争对手有何不同?我们将根据Synaptogenix的收益、风险、机构所有权、分析师建议、估值、股息和盈利能力,将其与类似公司进行比较。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and target prices for Synaptogenix and its rivals, as provided by MarketBeat.
这是由MarketBeat提供的Synaptogenix及其竞争对手的当前评级和目标价格细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Synaptogenix | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix Competitors | 3141 | 13133 | 39362 | 635 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
突触基因 | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix的竞争对手 | 3141 | 13133 | 39362 | 635 | 2.67 |
Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synaptogenix is more favorable than its rivals.
Synaptogenix目前的共识目标价为14.00美元,表明潜在上涨108.96%。作为一个整体,“药物制剂”公司有106.03%的潜在上行空间。考虑到Synaptogenix更高的共识评级和更高的可能上行空间,股票研究分析师显然认为Synaptogenix比它的竞争对手更有利。
Volatility and Risk
波动性和风险
Valuation and Earnings
估值和收益
This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.
此表比较了Synaptogenix及其竞争对手的营收、每股收益(EPS)和估值。
Gross Revenue | Net Income | Price/Earnings Ratio | |
Synaptogenix | N/A | -$12.61 million | -3.19 |
Synaptogenix Competitors | $1.83 billion | $243.52 million | -4.11 |
总收入 | 净收入 | 市盈率 | |
突触基因 | 不适用 | -1,261万元 | -3.19 |
Synaptogenix的竞争对手 | 18.3亿美元 | 2.4352亿美元 | -4.11 |
Synaptogenix's rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Synaptogenix的竞争对手比Synaptogenix的收入和收益更高。Synaptogenix的市盈率高于竞争对手,这表明它目前的价格高于同行业的其他公司。
Institutional and Insider Ownership
机构和内部人持股
9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by company insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Synaptogenix 9.1%的股份由机构投资者持有。相比之下,所有“医药制剂”公司42.0%的股份由机构投资者持有。Synaptogenix 1.9%的股份由公司内部人士持有。相比之下,所有“医药制剂”公司15.1%的股份由公司内部人持有。强大的机构持股表明,对冲基金、大型基金管理公司和捐赠基金相信,一只股票的长期表现将好于大盘。
Profitability
盈利能力
This table compares Synaptogenix and its rivals' net margins, return on equity and return on assets.
下表比较了Synaptogenix及其竞争对手的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Synaptogenix | N/A | -45.23% | -43.73% |
Synaptogenix Competitors | -3,202.84% | -160.99% | -24.58% |
净利润率 | 股本回报率 | 资产回报率 | |
突触基因 | 不适用 | -45.23% | -43.73% |
Synaptogenix的竞争对手 | -3,202.84% | -160.99% | -24.58% |
Summary
摘要
Synaptogenix rivals beat Synaptogenix on 7 of the 13 factors compared.
在比较的13个因素中,Synaptogenix的竞争对手在7个方面击败了Synaptogenix。
Synaptogenix Company Profile
Synaptogenix公司简介
(Get Rating)
(获取评级)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix公司是一家生物制药公司,在临床前和临床开发方面有候选产品。它专注于开发一个基于一种名为Bryostatin-1的候选药物的产品平台,用于治疗阿尔茨海默病。该公司还在评估bryostatin在其他神经退行性或认知疾病和功能障碍方面的治疗应用,如脆性X综合征、多发性硬化症和Niemann-Pick C型疾病。Synaptogenix公司与斯坦福大学、西奈山伊坎医学院以及利兰·斯坦福初级大学董事会签订了许可协议。该公司成立于2012年,总部设在纽约。
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synaptogenix Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synaptogenix和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧